Role of epigenetics in stem cell proliferation and differentiation: Implications for treating neurodegenerative diseases

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Srinageshwar, Bhairavi ^a   Maiti, Panchanan ^a,b   Dunbar, Gary L ^a,b   Rossignol, Julien ^a,c  

^a CENTRAL MICHIGAN UNIVERSITY   (United States)

^b Field Neurosciences Institute   (United States)

^c Children's Hospital of Michigan   (United States)

Author keywords

Alzheimer s disease; Epigenetics; Histone modifications; Huntington s disease; Induced pluripotent stem cells (iPSCs); Mesenchymal stem cells (MSCs); Neural stem cells (NSCs); Neurodegenerative diseases; Stem cells

Indexed keywords

MICRORNA 124; MICRORNA 9;

ALZHEIMER DISEASE; APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DEGENERATIVE DISEASE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE SILENCING; HISTONE MODIFICATION; HUMAN; NEUROFIBRILLARY TANGLE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN PHOSPHORYLATION; REVIEW; STEM CELL; ANIMAL; CYTOLOGY; GENETIC EPIGENESIS; GENETICS; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; NEURODEGENERATIVE DISEASES; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; CELL PROLIFERATION; EPIGENESIS, GENETIC; HUMANS; NEURAL STEM CELLS; NEURODEGENERATIVE DISEASES; NEUROGENESIS;

EID: 84956917735     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020199     Document Type: Review

References (92)

1. Sell, S. Stem Cells Handbook, 2nd ed.; Humana Press: New York, NY, USA, 2013.
2. Lakshmipathy, U.; Verfaillie, C. Stem cell plasticity. Blood Rev. 2005,19, 29-38. [CrossRef] [PubMed].
3. Gu, W.; Zhang, F.; Xue, Q.; Ma, Z.; Lu, P.; Yu, B. Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord. Neuropathology 2010, 30, 205-217. [CrossRef] [PubMed].
4. Song, C.H.; Honmou, O.; Ohsawa, N.; Nakamura, K.; Hamada, H.; Furuoka, H.; Hasebe, R.; Horiuchi, M. Effect of Transplantation of Bone Marrow-Derived Mesenchymal Stem cells on Mice Infected with Prions. J. Virol. 2009, 83, 5918-5927. [CrossRef] [PubMed].
5. Prockop, D.J.; Gregory, C.A.; Spees, J.L. One Strategy for Cell and Gene Therapy: Harnessing the Power of Adult Stem Cells to Repair Tissues. Proc. Natl. Acad. Sci. USA 2003,100,11917-11923. [CrossRef] [PubMed].
6. Blurton-Jones, M.; Spencer, B.; Michael, S.; Castello, N.A.; Agazaryan, A.A.; Davis, J.L.; Müller, F.J.; Loring, J.F.; Masliah, E.; LaFerla, F.M. Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models. Stem Cell Res. Ther. 2014, 5, 46. [CrossRef] [PubMed].
7. Crane, A.T.; Rossignol, J.; Dunbar, G.L. Use of Genetically Altered Stem Cells for the treatment of Huntington’s Disease. Brain Sci. 2014, 4, 202-219. [CrossRef] [PubMed].
8. D’Anglemont de Tassigny, X.; Pascual, A.; Löpez-Barneo, J. GDNF-based therapies, GDNF-producing interneurons, and trophic support of the dopaminergic nigrostriatal pathway. Implications for Parkinson’s disease. Front. Neuroanat. 2015, 9. [CrossRef].
9. Wyse, R.D.; Dunbar, G.L.; Rossignol, J. Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases. Int. J. Mol. Sci. 2014, 15, 1719-1745. [CrossRef] [PubMed].
10. Schu, S.; Nosov, M.; O’Flynn, L.; Shaw, G.; Treacy, O.; Barry, F.; Murphy, M.; O’Brien, T.; Ritter, T. Immunogenicity of Allogeneic Mesenchymal Stem Cells. J. Cell. Mol. Med. 2012,16, 2094-2103. [CrossRef] [PubMed].
11. Bifari, F.; Pacelli, L.; Krampera, M. Immunological properties of embryonic and adult stem cells. World J. Stem Cells. 2010, 2, 50-60. [CrossRef] [PubMed].
12. Boquest, A.C.; Noer, A.; Collas, P. Epigenetic programming of mesenchymal stem cells from human adipose tissue. Stem Cell. Rev. 2006,2, 319-329. [CrossRef] [PubMed].
13. Ariff, I.M.; Mitra, A.; Basu, A. Epigenetic Regulation of Self-Renewal and Fate determination in Neural Stem Cells. J. Neurosci. Res. 2012, 90, 529-539. [CrossRef] [PubMed].
14. Lunyak, V.V.; Rosenfeld, M.G. Epigenetic regulation of stem cell fate. Hum. Mol. Genet. 2008,17, R28-R36. [CrossRef] [PubMed].
15. Schmidt, R.; Plath, K. The roles of the reprogramming factors Oct4, Sox2 and Klf4 in resetting the somatic cell epigenome during induced pluripotent stem cell generation. Genome Biol. 2012, 13,251. [CrossRef] [PubMed].
16. Meissner, A. Epigenetic modifications in pluripotent and differentiated cells. Nat. Biotechnol. 2010, 28, 1079-1088. [CrossRef] [PubMed].
17. Isles, A.R.; Wilkinson, L.S. Epigenetics: What is it and why is it important to mental disease. Br. Med. Bull. 2008, 85, 35-45. [CrossRef] [PubMed].
18. D’Urso, A.; Brickner, J.H. Mechanisms of epigenetic memory. Trends Genet. 2014, 30, 230-236. [CrossRef] [PubMed].
19. Sweatt, J.D.; Nestler, E.J.; Meaney, M.J.; Akbarian, S. An Overview of the Molecular Basis of Epigenetics. In Epigenetic Regulation in the Nervous System—Basic Mechanisms and Clinical Impact; Elsevier: San Diego, CA, USA, 2013; pp. 3-33.
20. Bird, A.P. Perceptions of epigenetics. Nature 2007, 447, 396-398. [CrossRef] [PubMed].
21. Waddington, C.H. An Introduction to Modern Genetics. Proc. R. Entomol. Soc. Lond. Ser. A 1939,14, 82.
22. Stern, C.D.; Conrad, H. Waddington’s contributions to avian and mammalian development, 1930-1940. Int. J. Dev. Biol. 2000, 44, 15-22. [PubMed].
23. Barth, T.K.; Imhof, A. Fast signals and slow marks: The dynamics of histone modifications. Trends Biochem. Sci. 2010, 35, 618-626. [CrossRef] [PubMed].
24. Bhattacharya, S.; Zhang, Q.; Andersen, M.E. A deterministic map of Waddington’s epigenetic landscape for cell fate specification. BMC Syst. Biol. 2011, 5, 85. [CrossRef] [PubMed].
25. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403,41-45. [CrossRef] [PubMed].
26. Voigt, P.; Tee, W.W.; Reinberg, D. A double take on bivalent promoters. Genes Dev. 2013, 27, 1318-1338. [CrossRef] [PubMed].
27. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. Cell. Res. 2011, 21, 381-395. [CrossRef] [PubMed].
28. Delcuve, G.P.; Khan, D.H.; Davie, J.R. Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors. Clin. Epigenet. 2012, 4, 5. [CrossRef] [PubMed].
29. Hans, F.; Dimitrov, S. Histone H3 phosphorylation and cell division. Oncogene 2001,20,3021-3027. [CrossRef] [PubMed].
30. Ghavifekr Fakhr, M.; Farshdousti Hagh, M.; Shanehbandi, D.; Baradaran, B. DNA methylation pattern as important epigenetic criterion in cancer. Genet. Res. Int. 2013. [CrossRef] [PubMed].
31. Guillemette, B.; Drogaris, P.; Lin, H.H.; Armstrong, H.; Hiragami-Hamada, K.; Imhof, A.; Bonneil, E.; Thibault, P.; Verreault, A.; Festenstein, R.J. H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation. PLoS Genet. 2011, 7, e1001354. [CrossRef] [PubMed].
32. UK Essays. Targeting The Prostate Cancer Epigenome Biology Essay. Available online: http://www.ukessays.com/essays/biology/targeting-the-prostate-cancer-epigenome-biology-essay.php?cref=1 (accessed on 19 December 2015).
33. Kwon, S.J.; Park, J.H.; Park, E.J.; Lee, S.A.; Lee, H.S.; Kang, S.W.; Kwon, J. ATM-mediated phosphorylation of the chromatin remodeling enzyme BRG1 modulates DNA double-strand break repair. Oncogene 2015, 34, 303-313. [CrossRef] [PubMed].
34. Banerjee, T.; Chakravarti, D. A peek into the complex realm of histone phosphorylation. Mol. Cell. Biol. 2011, 31, 4858-4873. [CrossRef] [PubMed].
35. Sawicka, A.; Seiser, C. Sensing core histone phosphorylation—A matter of perfect timing. Biochim. Biophys. Acta 2014,1839, 711-718. [CrossRef] [PubMed].
36. Saetrom, P.; Sn0ve, O., Jr.; Rossi, J.J. Epigenetics and microRNAs. Pediatr. Res. 2007, 61,17-23. [CrossRef] [PubMed].
37. Song, Y.; Li, J.; Zhu, Y.; Dai, Y.; Zeng, T.; Liu, L.; Li, J.; Wang, H.; Qin, Y.; Zeng, M.; et al. MicroRNA-9 promotes tumor metastasis via repressing E-cadherin in esophageal squamous cell carcinoma. Oncotarget 2014, 5, 11669-11680. [CrossRef] [PubMed].
38. Xie, Y.; Zong, P.; Wang, W.; Liu, D.; Li, B.; Wang, Y.; Hu, J.; Ren, Y.; Qi, Y.; Cui, X. et al. Hypermethylation of potential tumor suppressor miR-34b/c is correlated with late clinical stage in patients with soft tissue sarcomas. Exp. Mol. Pathol. 2015, 98, 446-454. [CrossRef] [PubMed].
39. Garg, N.; Vijayakumarm, T.; Bakhshinyan, D.; Venugopal, C.; Singh, S.K. MicroRNA Regulation of Brain Tumour Initiating Cells in Central Nervous System Tumours. Stem Cells Int. 2015, 2015. [CrossRef] [PubMed].
40. Bonifer, C.; Cockerill, P.N. Chromatin mechanisms regulating gene expression in health and disease. Adv. Exp. Med. Biol. 2011, 711, 12-25. [PubMed].
41. Shao, Z.; Raible, F.; Mollaaghababa, R.; Guyon, J.R.; Wu, C.T.; Bender, W.; Kingston, R.E. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 1999, 98, 37-46. [CrossRef].
42. Norwood, L.E.; Grade, S.K.; Cryderman, D.E.; Hines, K.A.; Furiasse, N.; Toro, R.; Li, Y.; Dhasarathy, A.; Kladde, M.P.; Hendrix, M.J. et al. Conserved properties of HP1(Hsalpha). Gene 2004, 336, 37-46. [CrossRef] [PubMed].
43. Najafabadi, H.S.; Mnaimneh, S.; Schmitges, F.W.; Garton, M.; Lam, K.N.; Yang, A.; Albu, M.; Weirauch, M.T.; Radovani, E.; Kim, P.M. et al. C2H2 zinc finger proteins greatly expand the human regulatory lexicon. Nat. Biotechnol. 2015, 33, 555-562. [CrossRef] [PubMed].
44. Archer, T. Epigenetic Changes Induced by Exercise. J. Reward Defic. Syndr. 2015,1, 71-74.
45. Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol. Rev. 2010, 90, 905-981. [CrossRef] [PubMed].
46. HD Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993, 72, 971-983.
47. Valtieri, M.; Sorrentino, A. The mesenchymal stromal cell contribution to homeostasis. J. Cell. Physiol. 2008, 217,296-300. [CrossRef] [PubMed].
48. Wagner, W.; Feldmann, R.E., Jr.; Seckinger, A.; Maurer, M.H.; Wein, F.; Blake, J.; Krause, U.; Kalenka, A.; Bürgers, H.F.; Saffrich, R. et al. The heterogeneity of human mesenchymal stem cell preparations-Evidence from simultaneous analysis of proteomes and transcriptomes. Exp. Hematol. 2006, 34, 536-548. [CrossRef] [PubMed].
49. Phinney, D.G. Functional heterogeneity of mesenchymal stem cells: Implications for cell therapy. J. Cell. Biochem. 2012, 113, 2806-2812. [CrossRef] [PubMed].
50. Li, Z.; Liu, C.; Xie, Z.; Song, P.; Zhao, R.C.H.; Guo, L.; Liu, Z.; Wu, Y. Epigenetic Dysregulation in Mesenchymal Stem Cell Aging and Spontaneous Differentiation. PLoS ONE 2011, 6, e20526. [CrossRef] [PubMed].
51. Guo, L.; Zhou, Y.; Wang, S.; Wu, Y. Epigenetic changes of mesenchymal stem cells in three-dimensional (3D) spheroids. Cell. Mol. Med. 2014, 18, 2009-2019. [CrossRef] [PubMed].
52. Rossignol, J.; Fink, K.D.; Crane, A.T.; Davis, K.K.; Bombard, M.C.; Clerc, S.; Bavar, A.M.; Lowrance, S.A.; Song, C.; Witte, S. et al. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington’s disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number. Stem Cell Res. Ther. 2015, 6, 9. [CrossRef] [PubMed].
53. Teven, C.M.; Liu, X.; Hu, N.; Tang, N.; Kim, S.H.; Huang, E.; Yang, K.; Li, M.; Gao, J.L.; Liu, H. et al. Epigenetic regulation of mesenchymal stem cells: A focus on osteogenic and adipogenic differentiation. Stem Cells Int. 2011, 2011. [CrossRef] [PubMed].
54. Huang, B.; Li, G.; Jiang, X.H. Fate determination in mesenchymal stem cells: A perspective from histone-modifying enzymes. Stem Cell. Res. Ther. 2015, 6, 35. [CrossRef] [PubMed].
55. Walsh, D.M.; Selkoe, D.J. Oligomers on the brain: The emerging role of soluble protein aggregates in neurodegeneration. Protein Pept. Lett. 2004, 11, 213-228. [CrossRef] [PubMed].
56. Selkoe, D.J. The origins of Alzheimer disease: A is for amyloid. JAMA 2000, 283, 1615-1617. [CrossRef] [PubMed].
57. De Strooper, B. Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep. 2007, 8, 141-146. [CrossRef] [PubMed].
58. Jones, D.L.; Wagers, A.J. No place like home: Anatomy and function of the stem cell niche. Nat. Rev. Mol. Cell Biol. 2008, 9, 11-21. [CrossRef] [PubMed].
59. Lazarov, O.; Marr, R.A. Neurogenesis and Alzheimer’s disease: At the crossroads. Exp. Neurol. 2010, 223, 267-281. [CrossRef] [PubMed].
60. Fitzsimons, C.P.; van Bodegraven, E.; Schouten, M.; Lardenoije, R.; Kompotis, K.; Kenis, G.; van den Hurk, M.; Boks, M.P.; Biojone, C.; Joca, S. et al. Epigenetic regulation of adult neural stem cells: Implications for Alzheimer’s disease. Mol. Neurodegener. 2014, 9, 25. [CrossRef] [PubMed].
61. Caldwell, M.A.; He, X.; Wilkie, N.; Pollack, S.; Marshall, G.; Wafford, K.A.; Svendsen, C.N. Growth factors regulate the survival and fate of cells derived from human neurospheres. Nat. Biotechnol. 2001,19, 475-479. [CrossRef] [PubMed].
62. Singh, R.; Shiue, K.; Schomberg, D.; Zhou, F. Cellular epigenetic modifications of neural stem cell differentiation. Cell Transplant. 2009, 18, 1197-1211. [CrossRef] [PubMed].
63. Handel, A.E.; Ebers, G.C.; Ramagopalan, S.V. Epigenetics: Molecular mechanisms and implications for disease. Trends Mol. Med. 2010, 16, 7-16. [CrossRef] [PubMed].
64. Jawerka, M.; Colak, D.; Dimou, L.; Spiller, C.; Lagger, S.; Montgomery, R.L.; Olson, E.N.; Wurst, W.; Göttlicher, M.; Götz, M. The specific role of histone deacetylase 2 in adult neurogenesis. Neuron Glia Biol. 2010, 6, 93-107. [CrossRef] [PubMed].
65. Zhou, Q.; Dalgard, C.L.; Wynder, C.; Doughty, M.L. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells. BMC Neurosci. 2011, 12, 50. [CrossRef] [PubMed].
66. Hsieh, J.; Nakashima, K.; Kuwabara, T.; Mejia, E.; Gage, F.H. Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. USA 2004,101, 16659-16664. [CrossRef] [PubMed].
67. Hsieh, J.; Eisch, A.J. Epigenetics, hippocampal neurogenesis, and neuropsychiatric disorders: Unraveling the genome to understand the mind. Neurobiol. Dis. 2011, 39, 73-84. [CrossRef] [PubMed].
68. Jobe, E.M.; McQuate, A.L.; Zhao, X. Crosstalk among Epigenetic Pathways Regulates Neurogenesis. Front. Neurosci. 2012, 6, 59. [CrossRef] [PubMed].
69. Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. miRBase: MicroRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 2006, 34, D140-D144. [CrossRef] [PubMed].
70. Zhao, C.; Sun, G.; Li, S.; Lang, M.-F.; Yang, S.; Li, W.; Shi, Y. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc. Natl. Acad. Sci. USA 2010, 107, 1876-1881. [CrossRef] [PubMed].
71. Cheng, L.C.; Pastrana, E.; Tavazoie, M.; Doetsch, F. miR-124 regulates adult neurogenesis in the subventricular zone stem cell niche. Nat. Neurosci. 2009, 12, 399-408. [CrossRef] [PubMed].
72. Brohede, J.; Rinde, M.; Winblad, B.; Graff, C. A DNA methylation study of the amyloid precursor protein gene in several brain regions from patients with familial Alzheimer disease. J. Neurogenet. 2010, 24,179-181. [CrossRef] [PubMed].
73. Barrachina, M.; Ferrer, I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J. Neuropathol. Exp. Neurol. 2009, 68, 880-891. [CrossRef] [PubMed].
74. West, R.L.; Lee, J.M.; Maroun, L.E. Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer’s disease patient. J. Mol. Neurosci. 1995, 6,141-146. [CrossRef] [PubMed].
75. Femminella, G.D.; Ferrara, N.; Rengo, G. The emerging role of microRNAs in Alzheimer’s disease. Front. Physiol. 2015, 6, 40. [CrossRef] [PubMed].
76. Bicchi, I.; Morena, F.; Montesano, S.; Polidoro, M.; Martino, S. MicroRNAs and Molecular Mechanisms of Neurodegeneration. Genes 2013, 4, 244-263. [CrossRef] [PubMed].
77. Maciotta, S.; Meregalli, M.; Torrente, Y. The involvement of microRNAs in neurodegenerative diseases. Front. Cell. Neurosci. 2013, 7, 265. [CrossRef] [PubMed].
78. Takahashi, K.; Yamanaka, S. Induced pluripotent stem cells in medicine and biology. Development 2013,140, 2457-2461. [CrossRef] [PubMed].
79. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006,126, 663-676. [CrossRef] [PubMed].
80. Vaskova, E.A.; Stekleneva, A.E.; Medvedev, S.P.; Zakian, S.M. “Epigenetic memory” phenomenon in induced pluripotent stem cells. Acta Nat. 2013, 5, 15-21.
81. Stadtfeld, M.; Hochedlinger, K. Induced pluripotency: History, mechanisms, and applications. Genes Dev. 2010, 24, 2239-2263. [CrossRef] [PubMed].
82. Yamaguchi, S.; Hirano, K.; Nagata, S.; Tada, T. Sox2 expression effects on direct reprogramming efficiency as determined by alternative somatic cell fate. Stem Cells Res. 2011, 6,177-186. [CrossRef] [PubMed].
83. Shi, Y.; Ai, W. Function of KLF4 in Stem Cell Biology. In Pluripotent Stem Cells; Bhartiya, D., Ed.; Intech: Rijeka, Croatia, 2013.
84. Tansey, W.P. Mammalian MYC Proteins and Cancer. N. J. Sci. 2014, 2014. [CrossRef].
85. Baker, M. What does Nanog do? Nat. Rep. Stem Cells 2009. [CrossRef].
86. Tsialikas, J.; Romer-Seibert, J. LIN28: Roles and regulation in development and beyond. Development 2015, 142, 2397-2404. [CrossRef] [PubMed].
87. Shi, G.; Jin, Y. Role of Oct4 in maintaining and regaining stem cell pluripotency. Stem Cell Res. Ther. 2010,1, 39. [CrossRef] [PubMed].
88. Nishino, K.; Toyoda, M.; Yamazaki-Inoue, M.; Fukawatase, Y.; Chikazawa, E.; Sakaguchi, H.; Akutsu, H.; Umezawa, A. DNA methylation dynamics in human induced pluripotent stem cells over time. PLoS Genet. 2011, 9, e153-e160. [CrossRef] [PubMed].
89. Shao, K.; Koch, C.; Gupta, M.K.; Lin, Q.; Lenz, M.; Laufs, S.; Denecke, B.; Schmidt, M.; Linke, M.; Hennies, H.C. et al. Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol. Ther. 2013, 21, 240-250. [CrossRef] [PubMed].
90. Kim, K.; Doi, A.; Wen, B.; Ng, K.; Zhao, R.; Cahan, P.; Kim, J.; Aryee, M.J.; Ji, H.; Ehrlich, L.I. et al. Epigenetic memory in induced pluripotent stem cells. Nature 2010, 467, 285-290. [CrossRef] [PubMed].
91. Polo, J.M.; Liu, S.; Figueroa, M.E.; Kulalert, W.; Eminli, S.; Tan, K.Y.; Apostolou, E.; Stadtfeld, M.; Li, Y.; Shioda, T. et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 2010, 28, 848-855. [CrossRef] [PubMed].
92. Papp, B.; Plath, K. Epigenetics of reprogramming to induced pluripotency. Cell 2013, 152, 1324-1343. [CrossRef] [PubMed].